[
  {
    "question": "HIV patient with brain MRI showing single ring enhancing lesions and asked about the management",
    "option_a": "Sulfadiazine and pyrimethamine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "In HIV-positive patients, especially those with low CD4 counts, a ring-enhancing lesion on brain MRI most commonly suggests CNS toxoplasmosis. While multiple lesions are often seen, solitary lesions can occur as well. The standard management is to initiate empiric treatment for toxoplasmosis. CNS toxoplasmosis results from reactivation of latent Toxoplasma gondii infection in immunocompromised individuals. The parasite proliferates in brain tissue leading to necrosis and inflammation, which manifests as ring-enhancing lesions on imaging. Patients may present with focal neurological deficits, headache, confusion, seizures, or changes in mental status. The radiological appearance of a ring-enhancing lesion in an HIV patient strongly points towards toxoplasmosis, although primary CNS lymphoma remains a consideration if there is no clinical improvement. The recommended approach is to begin an empiric trial of anti-toxoplasmosis therapy. If there is a demonstrable clinical and radiological improvement over 10-14 days, the diagnosis is confirmed. Lack of improvement raises concern for alternative diagnoses such as primary CNS lymphoma, warranting further investigation with possible brain biopsy. The current standard of care is the combination of pyrimethamine, sulfadiazine, and leucovorin (folinic acid) as first-line therapy. Leucovorin is used to mitigate the bone marrow suppression associated with pyrimethamine. In pregnant patients, treatment regimens must be modified: spiramycin is often preferred in early pregnancy to reduce fetal transmission of toxoplasmosis, while after the first trimester, the risks and benefits of pyrimethamine-based regimens must be carefully weighed. Lactating women require careful evaluation of drug safety for the neonate. Option A lists only pyrimethamine and sulfadiazine, which constitute the core anti\u2010toxoplasmosis agents, but omits leucovorin, an essential adjunct to prevent hematologic toxicity. The marked answer (Option C) is presumed to include leucovorin with the pyrimethamine-sulfadiazine regimen, making it the more complete and correct management strategy. \u2022 In HIV patients with ring-enhancing brain lesions, always consider CNS toxoplasmosis as the top differential.  \u2022 Empirical anti-toxoplasmosis therapy is the initial management step.  \u2022 Reassess patient response clinically and radiographically after 10\u201314 days; failure to improve should prompt further workup for other diagnoses like primary CNS lymphoma. Recent guidelines from the CDC and HIV Medicine Association continue to endorse the use of pyrimethamine, sulfadiazine, and leucovorin as first-line therapy for CNS toxoplasmosis. Adjustments in therapy are recommended for special populations such as pregnant or lactating women, underscoring the need for individualized treatment plans based on risk\u2013benefit analyses.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_21.png"
  },
  {
    "question": "HIV patient with brain CT showing multiple ring-enhancing lesions, what is the next step?",
    "option_a": "CSF PCR",
    "option_b": "Serology",
    "option_c": "Biopsy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "In HIV patients with brain CT images showing multiple ring-enhancing lesions, the foremost diagnostic consideration is cerebral toxoplasmosis \u2013 an opportunistic infection due to reactivation of latent Toxoplasma gondii. The detection of IgG antibodies via serology is a key initial step that supports this diagnosis. In immunocompromised individuals, especially those with AIDS (commonly with CD4 counts <100 cells/mm\u00b3), latent Toxoplasma gondii cysts can reactivate. This reactivation leads to infection within the brain parenchyma and results in areas of necrosis surrounded by an inflammatory response, which then appear as ring-enhancing lesions on neuroimaging. Patients with cerebral toxoplasmosis may present with headache, focal neurological deficits, altered mental status, or seizures. The presence of multiple ring-enhancing lesions in an HIV-positive patient is highly suggestive of toxoplasmosis, although other differential diagnoses such as primary CNS lymphoma must also be considered. The initial work-up in such cases involves obtaining Toxoplasma gondii serology (IgG). A positive IgG implies prior exposure and supports the diagnosis of reactivation toxoplasmosis. Should the serology be negative, alternative diagnoses such as primary CNS lymphoma are more likely and necessitate further work-up (e.g., CSF PCR for EBV or brain biopsy in refractory cases). After confirming Toxoplasma exposure with a positive serology, the standard management is to initiate empirical anti-toxoplasmosis therapy \u2013 typically a combination regimen of pyrimethamine, sulfadiazine, and leucovorin. In cases where the patient is pregnant, pyrimethamine is contraindicated especially during the first trimester due to its teratogenicity; spiramycin is often used instead to reduce the risk of transplacental transmission. For lactating mothers, treatment regimens are chosen with caution regarding drug excretion into breast milk and potential neonatal effects. Clinical and radiologic improvement over a 2-week period helps confirm the diagnosis. Option A (CSF PCR) is less appropriate initially because it is not the primary diagnostic tool for toxoplasmosis and is typically reserved for evaluating primary CNS lymphoma (often by detecting EBV DNA). Option C (Biopsy) is invasive and is usually considered only if there is no clinical improvement with empirical therapy. The marked answer, Option B (Serology), is the appropriate next step as it helps confirm prior exposure to Toxoplasma gondii, thereby supporting the likely diagnosis of cerebral toxoplasmosis. A positive Toxoplasma IgG in an HIV patient with multiple ring-enhancing lesions strongly favors cerebral toxoplasmosis. Empirical treatment with anti-toxoplasmosis medications is often initiated concurrently with serologic testing. Improvement on therapy aids in solidifying the diagnosis, while failure to respond should prompt consideration of alternative entities such as primary CNS lymphoma. Current guidelines, including those from the Infectious Diseases Society of America (IDSA), advocate for Toxoplasma gondii serologic testing and prompt initiation of empirical therapy in HIV patients presenting with ring-enhancing brain lesions. Recent studies have reinforced this approach, indicating that early treatment improves neurological outcomes. Moreover, management strategies are tailored for special populations; for instance, pregnant patients are managed with agents like spiramycin to avoid teratogenic risks, and lactating patients receive careful review of medication excretion profiles.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_13.png"
  },
  {
    "question": "Sickler patient has back pain and lower limb weakness, on examination he has back tenderness. What is the organism?",
    "option_a": "staphylococcus aureus",
    "option_b": "TB",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "Sickle cell disease predisposes patients to osteomyelitis due to vaso-occlusive events that cause bone infarcts, as well as functional asplenia that impairs the clearance of encapsulated organisms. Consequently, although Staphylococcus aureus is the most common cause of osteomyelitis in the general population, Salmonella species are notably implicated in sickle cell patients. Recurrent vaso-occlusive crises in sickle cell disease cause bone infarctions and local ischemia, which compromise bone integrity and local immune responses. Functional asplenia further increases susceptibility to infections with encapsulated organisms such as Salmonella. This background fosters hematogenous seeding of the bone, leading to osteomyelitis and, in some cases, epidural abscess formation that may compress neural structures. A patient with sickle cell disease presenting with back pain, back tenderness, and lower limb weakness raises concern for vertebral osteomyelitis, possibly complicated by an epidural abscess. The lower limb weakness suggests spinal cord or nerve root involvement, which necessitates urgent evaluation. In this context, Salmonella is the most likely pathogen. Key differentials include osteomyelitis due to Staphylococcus aureus and tuberculous spondylitis (Pott's disease). The diagnostic work-up should include blood cultures, inflammatory markers, and spinal imaging\u2014preferably MRI\u2014to assess for osteomyelitis and any associated epidural abscess. Biopsy may be required to confirm the organism, especially when initial cultures are inconclusive. Management involves initiating targeted intravenous antibiotic therapy. Current guidelines recommend third-generation cephalosporins (e.g., ceftriaxone), which cover Salmonella and are safe for use in pregnant and lactating patients. In cases where there is neurological compromise due to epidural abscess formation, prompt neurosurgical evaluation for decompression and possible abscess drainage is warranted. Option A (Staphylococcus aureus) is a common cause of osteomyelitis in the general population but is less likely in sickle cell patients. Option B (TB) could be considered in endemic areas or with a chronic course, but it is less likely given the typical presentation in this population. Option C, though not explicitly described, is presumed to be Salmonella\u2014the most appropriate answer given the patient's risk factors. Option D is not provided. In sickle cell disease, always maintain a high index of suspicion for Salmonella osteomyelitis even when the presentation might mimic other spinal infections. Rapid diagnosis and prompt treatment are crucial to prevent complications such as spinal cord compression. For pregnant or lactating patients, antibiotic choices must ensure maternal efficacy while minimizing fetal or neonatal risks. Recent clinical studies and guidelines, including those from the Infectious Diseases Society of America (IDSA), emphasize the increased risk of Salmonella osteomyelitis in sickle cell patients. Evidence supports the use of ceftriaxone as first-line therapy due to its safety profile in pregnancy and lactation, making it an ideal choice for these patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of young male, IV drug user presented with fever and hemiparesis, what will you do?",
    "option_a": "Start antibiotics",
    "option_b": "Anti-platelets",
    "option_c": "Anticoagulation",
    "option_d": "tPA",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "In patients with a history of intravenous drug use presenting with fever and focal neurological deficits (such as hemiparesis), the foremost concern is an infectious etiology \u2013 most notably infective endocarditis with septic emboli or secondary brain abscess formation. The clinical scenario demands prompt evaluation for infection rather than an ischemic or hemorrhagic stroke. IV drug use predisposes individuals to bacteremia and infective endocarditis. Vegetations on heart valves can dislodge, leading to septic emboli that travel to the brain. These emboli may cause infarction or serve as a nidus for abscess formation. Bacterial invasion and inflammatory response in the brain parenchyma are responsible for local tissue damage and neurological deficits. The presence of fever in combination with focal neurological signs such as hemiparesis in an IV drug user is highly suggestive of an infectious process. The neurologic deficits are often due to embolic events causing stroke or abscesses that may compress adjacent brain tissue. Early recognition is essential to prevent further complications. The evaluation should include urgent neuroimaging (preferably MRI for better sensitivity for abscess detection), blood cultures, and an echocardiogram (transesophageal if needed) to assess for valvular vegetations. Differential diagnoses include ischemic stroke unrelated to infection, hemorrhagic stroke, and noninfectious causes of neurological deficits. Correlating the evidence of infection (fever, positive cultures) is critical. According to current guidelines, initial management involves prompt initiation of broad\u2010spectrum intravenous antibiotics after obtaining blood cultures. Empiric coverage should target organisms commonly seen in IV drug users (including Staphylococcus aureus). Neurosurgical consultation is warranted if there is evidence of abscess formation or significant mass effect. In pregnant and lactating patients, antibiotic regimens should be selected considering fetal and neonatal safety; penicillin-based regimens are generally preferred when appropriate, and alternative agents should be used if contraindications exist. Option A (Start antibiotics) is correct because immediate treatment of the suspected infection is vital. Option B (Anti-platelets) is used for vascular infarcts but does not address an infectious process. Option C (Anticoagulation) is contraindicated in infective endocarditis due to the risk of hemorrhage. Option D (tPA) is used for acute ischemic stroke but is dangerous in the context of septic embolism where hemorrhagic transformation is a risk. 1. IV drug use is a red flag for infective endocarditis with potential septic emboli. 2. Always obtain blood cultures before starting antibiotics. 3. Focal neurological deficits with fever should prompt a search for an infectious source. Recent updates from the American Heart Association emphasize prompt diagnosis and early antibiotic intervention in suspected infective endocarditis to minimize embolic complications. Studies continue to support rapid imaging and the use of broad\u2010spectrum antibiotics in these patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "What carries the worst prognosis for brain abscess?",
    "option_a": "Being close to ventricles",
    "option_b": "Changes in level of consciousness at time when start treatment",
    "option_c": "(Anticoagulation) is contraindicated in infective endocarditis due to the risk of hemorrhage. Option D (tPA) is used for acute ischemic stroke but is dangerous in the context of septic embolism where hemorrhagic transformation is a risk.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "In patients with a history of intravenous drug use presenting with fever and focal neurological deficits (such as hemiparesis), the foremost concern is an infectious etiology \u2013 most notably infective endocarditis with septic emboli or secondary brain abscess formation. The clinical scenario demands prompt evaluation for infection rather than an ischemic or hemorrhagic stroke. IV drug use predisposes individuals to bacteremia and infective endocarditis. Vegetations on heart valves can dislodge, leading to septic emboli that travel to the brain. These emboli may cause infarction or serve as a nidus for abscess formation. Bacterial invasion and inflammatory response in the brain parenchyma are responsible for local tissue damage and neurological deficits. The presence of fever in combination with focal neurological signs such as hemiparesis in an IV drug user is highly suggestive of an infectious process. The neurologic deficits are often due to embolic events causing stroke or abscesses that may compress adjacent brain tissue. Early recognition is essential to prevent further complications. The evaluation should include urgent neuroimaging (preferably MRI for better sensitivity for abscess detection), blood cultures, and an echocardiogram (transesophageal if needed) to assess for valvular vegetations. Differential diagnoses include ischemic stroke unrelated to infection, hemorrhagic stroke, and noninfectious causes of neurological deficits. Correlating the evidence of infection (fever, positive cultures) is critical. According to current guidelines, initial management involves prompt initiation of broad\u2010spectrum intravenous antibiotics after obtaining blood cultures. Empiric coverage should target organisms commonly seen in IV drug users (including Staphylococcus aureus). Neurosurgical consultation is warranted if there is evidence of abscess formation or significant mass effect. In pregnant and lactating patients, antibiotic regimens should be selected considering fetal and neonatal safety; penicillin-based regimens are generally preferred when appropriate, and alternative agents should be used if contraindications exist. Option A (Start antibiotics) is correct because immediate treatment of the suspected infection is vital. Option B (Anti-platelets) is used for vascular infarcts but does not address an infectious process. Option C (Anticoagulation) is contraindicated in infective endocarditis due to the risk of hemorrhage. Option D (tPA) is used for acute ischemic stroke but is dangerous in the context of septic embolism where hemorrhagic transformation is a risk. 1. IV drug use is a red flag for infective endocarditis with potential septic emboli. 2. Always obtain blood cultures before starting antibiotics. 3. Focal neurological deficits with fever should prompt a search for an infectious source. Recent updates from the American Heart Association emphasize prompt diagnosis and early antibiotic intervention in suspected infective endocarditis to minimize embolic complications. Studies continue to support rapid imaging and the use of broad\u2010spectrum antibiotics in these patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of patient presenting with headache, normal brain CT and LP done by an intern and showed 48 WBCs, 780 RBCs, normal protein and glucose",
    "option_a": "Traumatic Tap",
    "option_b": "Viral meningitis",
    "option_c": "Bacterial meningitis",
    "option_d": "SAH? xanthochromia",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "In patients with a history of intravenous drug use presenting with fever and focal neurological deficits (such as hemiparesis), the foremost concern is an infectious etiology \u2013 most notably infective endocarditis with septic emboli or secondary brain abscess formation. The clinical scenario demands prompt evaluation for infection rather than an ischemic or hemorrhagic stroke. IV drug use predisposes individuals to bacteremia and infective endocarditis. Vegetations on heart valves can dislodge, leading to septic emboli that travel to the brain. These emboli may cause infarction or serve as a nidus for abscess formation. Bacterial invasion and inflammatory response in the brain parenchyma are responsible for local tissue damage and neurological deficits. The presence of fever in combination with focal neurological signs such as hemiparesis in an IV drug user is highly suggestive of an infectious process. The neurologic deficits are often due to embolic events causing stroke or abscesses that may compress adjacent brain tissue. Early recognition is essential to prevent further complications. The evaluation should include urgent neuroimaging (preferably MRI for better sensitivity for abscess detection), blood cultures, and an echocardiogram (transesophageal if needed) to assess for valvular vegetations. Differential diagnoses include ischemic stroke unrelated to infection, hemorrhagic stroke, and noninfectious causes of neurological deficits. Correlating the evidence of infection (fever, positive cultures) is critical. According to current guidelines, initial management involves prompt initiation of broad\u2010spectrum intravenous antibiotics after obtaining blood cultures. Empiric coverage should target organisms commonly seen in IV drug users (including Staphylococcus aureus). Neurosurgical consultation is warranted if there is evidence of abscess formation or significant mass effect. In pregnant and lactating patients, antibiotic regimens should be selected considering fetal and neonatal safety; penicillin-based regimens are generally preferred when appropriate, and alternative agents should be used if contraindications exist. Option A (Start antibiotics) is correct because immediate treatment of the suspected infection is vital. Option B (Anti-platelets) is used for vascular infarcts but does not address an infectious process. Option C (Anticoagulation) is contraindicated in infective endocarditis due to the risk of hemorrhage. Option D (tPA) is used for acute ischemic stroke but is dangerous in the context of septic embolism where hemorrhagic transformation is a risk. 1. IV drug use is a red flag for infective endocarditis with potential septic emboli. 2. Always obtain blood cultures before starting antibiotics. 3. Focal neurological deficits with fever should prompt a search for an infectious source. Recent updates from the American Heart Association emphasize prompt diagnosis and early antibiotic intervention in suspected infective endocarditis to minimize embolic complications. Studies continue to support rapid imaging and the use of broad\u2010spectrum antibiotics in these patients.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_23.png"
  },
  {
    "question": "VZV most common location in the neuronal axis",
    "option_a": "thoracic",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Varicella zoster virus (VZV) causes chickenpox during primary infection and establishes latency in sensory nerve ganglia, particularly in the dorsal root ganglia. On reactivation, typically in older or immunocompromised individuals, it manifests as herpes zoster (shingles). The thoracic region is the most commonly affected area because the thoracic dorsal root ganglia are numerous and frequently involved. Following the primary infection (chickenpox), VZV becomes dormant in sensory ganglia including cranial nerves and dorsal root ganglia. Reactivation, which can be triggered by stress, aging, or immunosuppression, leads to viral replication. This causes inflammation and damage along the nerve, most commonly in the thoracic dermatomes, resulting in the characteristic unilateral, vesicular rash and pain. Clinically, herpes zoster typically presents as a painful, unilateral, dermatomal rash. While it can occur anywhere along the sensory distribution, it most frequently affects the thoracic region (T3-T12), leading to a rash commonly seen on the chest or back. Diagnosis is primarily clinical, based on the characteristic rash and patient history. In atypical cases or when confirmation is needed, laboratory tests such as PCR for VZV, Tzanck smear, or direct fluorescent antibody testing can be performed. Differential diagnoses include contact dermatitis, herpes simplex, and other causes of neuropathic pain. The mainstay of treatment is early initiation of antiviral therapy (acyclovir, valacyclovir, or famciclovir), ideally within 72 hours of rash onset to decrease acute symptoms and reduce the risk of postherpetic neuralgia. Pain control using analgesics, gabapentin, or NSAIDs is also essential. In pregnant or lactating women, acyclovir is generally considered safe when the benefits outweigh potential risks, though it is important to carefully assess each patient's clinical situation. Vaccination against VZV is recommended in older adults to prevent shingles. Although the provided options are incomplete, the answer 'thoracic' is supported by epidemiological and clinical data as the most frequent site for VZV reactivation in the neuronal axis. Other distractors such as cranial or lumbosacral are less common. Remember that shingles most commonly affects the thoracic dermatomes. Early antiviral treatment is critical in reducing the progression and complications of the disease, notably postherpetic neuralgia. Always consider special populations like pregnant and lactating women, where risk-benefit analyses guide treatment choices. Recent clinical guidelines emphasize early antiviral therapy to prevent serious complications and reduce pain. Current research continues to support the use of acyclovir and its analogs as effective treatments for herpes zoster. In special populations such as pregnant or breastfeeding women, treatment decisions are made on an individual basis, with acyclovir generally regarded as safe when indicated.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario with history of oculomasticatory myorhythmia",
    "option_a": "Biopsy from the jejunum",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Oculomasticatory myorhythmia is an extremely rare but pathognomonic sign of Whipple's disease, a systemic infection caused by Tropheryma whipplei. The characteristic rhythmic movements of the eyes and masticatory muscles point strongly toward this diagnosis. Whipple's disease results from infection with the gram\u2010positive bacillus Tropheryma whipplei. It leads to an infiltration of foamy, periodic acid\u2013Schiff (PAS)-positive macrophages in affected tissues (most commonly the small intestine), and may also produce neurological involvement. The abnormal deposition of these organisms and the ensuing inflammatory response result in the distinctive myorhythmia seen in some cases. Patients classically present with chronic symptoms such as weight loss, diarrhea, and arthralgias. However, the neurological variant may present with oculomasticatory myorhythmia; thus, when this clinical sign is noted, one must consider Whipple's disease even in the absence of overt gastrointestinal symptoms. The gold standard diagnosis involves obtaining a biopsy from the small intestine (duodenal or jejunal) and demonstrating PAS-positive macrophages. Additional testing including PCR for T. whipplei can increase sensitivity, and in cases with neurological involvement, cerebrospinal fluid (CSF) PCR may be useful. Differential diagnoses include other inflammatory or infectious gastroenteropathies but the presence of oculomasticatory myorhythmia is uniquely characteristic of Whipple\u2019s disease. First-line treatment for Whipple's disease involves an initial course of intravenous antibiotics (typically ceftriaxone) for 2\u20134 weeks, followed by long-term oral therapy with trimethoprim-sulfamethoxazole for 1\u20132 years. In pregnancy and lactation, antibiotic choices must be carefully considered; ceftriaxone is generally regarded as safe during pregnancy when indicated, but TMP-SMX is contraindicated during the first trimester and near term, so alternative regimens may be required. Option A (Biopsy from the jejunum) is correct because it directly leads to histologic confirmation by revealing PAS-positive macrophages. Although other options were not provided, none would be as definitive for a suspected case of Whipple's disease presenting with oculomasticatory myorhythmia. 1. Oculomasticatory myorhythmia is one of the few clinical signs that is essentially pathognomonic for Whipple's disease. 2. Small bowel biopsy (duodenal or jejunal) is the cornerstone of diagnosis. 3. Always consider systemic involvement in patients with atypical neurological signs. Recent studies emphasize the utility of molecular methods (PCR) in improving diagnostic sensitivity for T. whipplei. Guidelines now recommend combining histopathology with molecular testing to confirm the diagnosis, particularly in cases with predominant neurological features.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of HIV patient presented with new neurological focality and brain MRI showed two non-enhancing white matter lesions",
    "option_a": "PML",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Progressive multifocal leukoencephalopathy (PML) is an opportunistic demyelinating condition seen mostly in immunocompromised individuals, such as those with HIV/AIDS. It is caused by reactivation of the JC virus, usually in patients with low CD4 counts. In PML, the JC virus reactivates in the setting of impaired cellular immunity. The virus infects oligodendrocytes, leading to demyelination and the formation of characteristic white matter lesions. These lesions are typically non-enhancing on MRI due to the lack of an inflammatory response in the immunosuppressed state. HIV patients presenting with new focal neurological deficits should raise suspicion for PML, especially when brain imaging reveals white matter lesions. The lack of enhancement helps differentiate it from other lesions such as toxoplasmosis or primary CNS lymphoma, which usually show enhancement due to associated inflammation or breakdown of the blood-brain barrier. The radiologic hallmark is non-enhancing multifocal white matter lesions on T2/FLAIR images. Confirmation is achieved via CSF analysis for JC virus DNA using PCR. Differential diagnoses include CNS lymphoma (which typically enhances), toxoplasmosis (ring-enhancing lesions), and other demyelinating conditions. The cornerstone of management is immune reconstitution. In HIV patients, this means optimizing antiretroviral therapy (ART) to improve immune function. There is no specific antiviral therapy against JC virus; however, supportive care and cautious monitoring for immune reconstitution inflammatory syndrome (IRIS) are important. For pregnant or lactating women with HIV, ART regimens must be carefully selected to ensure both maternal health and fetal safety. Option A (PML) is correct because the clinical scenario of an HIV patient with new focal neurological deficits and non-enhancing white matter lesions is most consistent with PML. Other options, while not listed here, would likely not match the characteristic imaging and clinical profile of PML. 1. In HIV-positive patients, non-enhancing white matter lesions should prompt evaluation for PML. 2. CSF PCR for JC virus is critical for diagnostic confirmation. 3. Optimization of ART is the key therapeutic intervention. Recent updates stress the importance of early ART initiation and reconstitution of immune function to manage PML. New research is ongoing to find targeted antivirals, though none has yet supplanted immune restoration as the mainstay of therapy.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_18.png"
  },
  {
    "question": "Case of rapid progressive dementia (5 weeks history), with visual field defects and normal MRI",
    "option_a": "CJD",
    "option_b": "PML",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Creutzfeldt-Jakob Disease (CJD) is a rare, fatal neurodegenerative prion disease characterized by rapidly progressive dementia. The Heidenhain variant of CJD, in particular, presents with prominent visual disturbances, including visual field defects. CJD is caused by the misfolding of normal prion protein into a pathogenic form, leading to spongiform changes in the brain. This abnormal protein accumulation causes widespread neuronal loss and gliosis. Although MRI abnormalities (especially diffusion-weighted imaging changes) are common, very early in the disease course the MRI may appear normal. Rapidly progressive dementia over a few weeks along with visual field deficits is highly suggestive of the Heidenhain variant of CJD. Patients may also develop myoclonus and other neurological deficits as the disease advances. The diagnostic workup for CJD includes MRI (typically showing cortical ribboning or basal ganglia hyperintensities on DWI), EEG (which may show periodic sharp wave complexes), and CSF studies (detection of 14-3-3 protein and, more recently, RT-QuIC testing). Differential diagnoses include autoimmune encephalitis, toxic-metabolic encephalopathies, and other rapidly progressive dementias. Currently, there is no curative treatment for CJD. Management is supportive and palliative, focusing on symptom control and quality of life. In the context of pregnancy and lactation, supportive care protocols remain the same, emphasizing comfort and ethical considerations in decision-making. Option A (CJD) is considered correct in this scenario due to the rapid progression of dementia, the presence of visual field deficits (indicative of the Heidenhain variant), and even though the MRI is initially normal, early disease may not yet demonstrate imaging abnormalities. Other options (if provided) are less consistent with this clinical picture. 1. The Heidenhain variant of CJD should be considered in cases of rapid progressive dementia with early visual disturbances. 2. MRI findings in CJD typically become evident later in the course of the disease. 3. CSF RT-QuIC has emerged as a highly sensitive and specific diagnostic tool. Recent advances include the increased utilization of RT-QuIC in CSF, which has improved diagnostic accuracy. Current guidelines stress a multimodal diagnostic approach given that early MRI changes may be absent in some patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Nurse got needle stick in her finger after blood extraction from a patient, she refuses to report it to infections control because the patient looks fine:",
    "option_a": "(Report the incident) is correct because it initiates the entire post",
    "option_b": "(Respect the nurse\u2019s need) is incorrect because personal discomfort or perception of the patient\u2019s health status should not override established safety protocols. Option C (Check the patient file) is insufficient as an isolated measure since immediate reporting is mandatory. Option D (Screen the patient for HIV, HBV, and HCV) is not appropriate as the first step without proper reporting and coordination with infection control.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Needle stick injuries are a recognized occupational hazard for healthcare workers, potentially exposing them to blood-borne pathogens such as HIV, hepatitis B (HBV), and hepatitis C (HCV). Immediate reporting of such injuries is critical to initiate appropriate evaluation and prophylaxis. The transmission of blood-borne viruses occurs when contaminated blood is inoculated into a healthcare worker\u2019s bloodstream through a needle stick. The risk of infection depends on the type of pathogen, the amount of blood, and the immune status of the exposed individual. Even if the source patient appears healthy, many blood-borne infections (like HIV and hepatitis) can be asymptomatic in their early stages. Timely reporting ensures that the exposed individual receives proper risk assessment and post-exposure prophylaxis (PEP) if indicated. Following a needle stick injury, the immediate action is to report the incident to the infection control team. A risk assessment is then performed, which includes baseline testing for HIV, HBV, and HCV, and evaluation of the need for PEP. Delaying reporting could compromise the effectiveness of any prophylactic measures. First-line management is the prompt reporting of the incident, followed by immediate baseline evaluation (serologic testing for HIV, HBV, HCV) and risk stratification to determine the need for PEP. For HIV exposure, antiretroviral therapy (ART) should be initiated as soon as possible, ideally within hours. In pregnant or lactating healthcare workers, PEP regimens are adjusted according to safety profiles with preferred agents recommended by current CDC guidelines. Option A (Report the incident) is correct because it initiates the entire post-exposure management protocol, including timely evaluation, risk stratification, and initiation of PEP. Option B (Respect the nurse\u2019s need) is incorrect because personal discomfort or perception of the patient\u2019s health status should not override established safety protocols. Option C (Check the patient file) is insufficient as an isolated measure since immediate reporting is mandatory. Option D (Screen the patient for HIV, HBV, and HCV) is not appropriate as the first step without proper reporting and coordination with infection control. 1. Immediate reporting of a needle stick injury is crucial to maximize the effectiveness of post-exposure prophylaxis. 2. Blood-borne infections can be asymptomatic; thus, the source's apparent health is not a reliable indicator of safety. 3. Time is of the essence\u2014the effectiveness of PEP declines significantly with delayed initiation. Current CDC and WHO guidelines continue to emphasize immediate reporting and prompt initiation of PEP. Recent research underlines that delayed management of needle stick injuries increases the risk for seroconversion, hence the critical nature of early intervention even if the source patient appears well.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "HIV patient with brain CT showing multiple ring enhancing lesions, what is the next step?",
    "option_a": "CSF PCR",
    "option_b": "Serology (most likely Toxoplasmosis)",
    "option_c": "Biopsy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "In HIV\u2010infected patients with a low CD4 count, multiple ring\u2010enhancing lesions on CT are classically associated with reactivation of latent Toxoplasma gondii infection. The clinical scenario calls for confirming the diagnosis of cerebral toxoplasmosis before embarking on definitive therapy. In immunocompromised patients, reactivation of latent Toxoplasma gondii leads to focal necrotic lesions with surrounding inflammation in the brain. The parasite, normally kept in check by T-cell mediated immunity, proliferates when the immune system is suppressed, leading to lesion formation that appears as ring\u2010enhancing areas on imaging. Patients typically present with headache, focal neurological deficits, confusion, or seizures. The imaging finding of multiple ring\u2010enhancing lesions is highly suggestive of toxoplasmosis, though primary CNS lymphoma is an important alternative consideration, especially in patients with a negative Toxoplasma IgG. The differential includes cerebral toxoplasmosis, primary CNS lymphoma, tuberculomas, and fungal abscesses. Toxoplasma IgG serology is usually obtained; a positive result in the appropriate clinical setting supports the diagnosis. CSF PCR for Toxoplasma has lower sensitivity, and brain biopsy is reserved for cases not responding to empirical therapy. Once Toxoplasma\u2013specific serology is positive and clinical/imaging findings are consistent, first-line treatment is initiated with a combination regimen of pyrimethamine, sulfadiazine, and leucovorin for 6 weeks, with extension based on clinical response. In pregnancy, management is modified: spiramycin is used in acute maternal infection (especially early gestation) to reduce transplacental transmission, though central nervous system involvement usually necessitates a careful risk/benefit discussion with possible combination therapy under close monitoring. Option A (CSF PCR) is less sensitive and not preferred as the next diagnostic step. Option B (Serology for Toxoplasma) is non-invasive and widely used to support the presumed diagnosis, making it the correct next step. Option C (Biopsy) is invasive and reserved for cases where empirical therapy fails or diagnosis is unclear. \u2022 Toxoplasmosis is the most common cause of intracerebral lesions in AIDS patients. \u2022 A positive Toxoplasma IgG serology in this clinical context makes toxoplasmosis highly likely. \u2022 Empirical therapy is often started based on serologic and radiologic findings, with clinical improvement supporting the diagnosis. Recent guidelines from the Infectious Diseases Society of America (IDSA) continue to endorse the use of Toxoplasma IgG serology as an essential step in the diagnostic evaluation of HIV patients with brain ring-enhancing lesions, with emphasis on early empirical treatment to improve outcomes.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_31.png"
  },
  {
    "question": "Same scenario what is the treatment:",
    "option_a": "Fluconazole",
    "option_b": "Amphotericin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "After confirming that the most likely diagnosis is cerebral toxoplasmosis in an HIV patient, the next critical management step is initiating appropriate antiparasitic therapy. Toxoplasma gondii reactivation leads to focal necrotizing encephalitis. The treatment works by inhibiting folate synthesis in the parasite, thereby stopping its replication and allowing the immune system (or additional supportive measures) to clear the infection. Clinically, patients exhibit neurological deficits, and timely initiation of effective therapy often results in improvement of symptoms and radiographic resolution of lesions over several weeks. Differentiation from primary CNS lymphoma is primarily through imaging findings, serologic test results, and response to therapy. A trial of anti-toxoplasma therapy is both diagnostic and therapeutic; if lesions improve clinically and radiologically, the diagnosis is confirmed. First-line treatment for cerebral toxoplasmosis includes a combination regimen of pyrimethamine (which directly inhibits parasitic folate synthesis), sulfadiazine (to provide synergistic bactericidal activity), and leucovorin (folinic acid) to counteract bone marrow toxicity. This combination is typically administered for at least 6 weeks, with treatment duration adjusted based on clinical and radiological response. For pregnant patients, treatment modifications are needed: spiramycin is preferred in early pregnancy to reduce fetal transmission, although CNS disease may necessitate the use of the standard regimen with careful monitoring and informed risk-benefit assessment. Option A (Fluconazole) and Option B (Amphotericin) are antifungals and are not effective against Toxoplasma gondii. Option C is assumed to represent the appropriate anti-toxoplasmosis regimen (i.e., pyrimethamine plus sulfadiazine and leucovorin), making it the correct treatment choice. \u2022 Empirical treatment for cerebral toxoplasmosis typically results in improvement within 10-14 days, supporting the diagnosis. \u2022 Leucovorin is essential to prevent hematologic toxicity from pyrimethamine. \u2022 Close monitoring for drug side effects is critical during treatment. Guidelines from IDSA and recent reviews in neurology literature reaffirm the combination of pyrimethamine, sulfadiazine, and leucovorin as the mainstay of treatment for cerebral toxoplasmosis, emphasizing early treatment initiation for improved patient outcomes.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Neuro-brucellosis what to give (no rifampin or Bactrim in the choices)",
    "option_a": "Doxycycline",
    "option_b": "Ceftriaxone",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neurobrucellosis is a rare but serious complication of systemic brucellosis, in which Brucella bacteria invade the central nervous system. Treatment typically requires agents that can cross the blood-brain barrier effectively. Brucella species are intracellular pathogens that can evade immune responses and localize within the CNS. The infection causes meningeal irritation and/or encephalitis. Successful treatment requires antibiotics with high intracellular penetration and good cerebrospinal fluid (CSF) penetration. Patients with neurobrucellosis may present with symptoms of meningitis, encephalitis, or focal neurological deficits. CSF analysis typically shows lymphocytic pleocytosis, and although eosinophilia is less classic, an inflammatory response can occasionally produce mixed pictures. The differential diagnosis includes tubercular meningitis, fungal meningitis, and other bacterial infections. Diagnosis is supported by history of exposure (e.g., contact with animals or unpasteurized dairy products), positive serologic tests for Brucella, and compatible CSF findings. The standard treatment for brucellosis generally includes a combination of doxycycline and rifampin. However, when managing neurobrucellosis\u2014especially when rifampin and TMP/SMX (Bactrim) are not available or contraindicated\u2014a regimen that includes agents with excellent CNS penetration is necessary. Ceftriaxone, a third-generation cephalosporin, is known for its effective penetration into the CSF and can be effectively combined with doxycycline in treating neurobrucellosis. The typical duration of therapy is extended (6 weeks or more). In pregnant patients, doxycycline is generally avoided due to its effects on fetal bone and teeth development; thus, ceftriaxone is a safer option, making its selection even more appropriate in this scenario. Option A (Doxycycline) is a cornerstone in brucellosis therapy but has limitations in CNS penetration and contraindications in pregnancy. Option B (Ceftriaxone) offers excellent CNS penetration and is favored in neurobrucellosis, especially when rifampin or Bactrim are not among the choices, making it the best available answer. \u2022 Neurobrucellosis requires prolonged combination antibiotic therapy. \u2022 Ceftriaxone\u2019s ability to cross the blood-brain barrier makes it a key agent in CNS infections. \u2022 In pregnant patients, the avoidance of tetracyclines (like doxycycline) highlights the importance of alternative agents such as ceftriaxone. Recent reviews and consensus guidelines support the use of ceftriaxone as part of a combination regimen for neurobrucellosis, particularly emphasizing its CNS penetration and safety profile, especially in special populations such as pregnant women.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with CSF pic of lymphocytosis and eosinophilia showing schistosomiasis what is the treatment",
    "option_a": "praziquantel",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Schistosomiasis is a parasitic infection caused by trematode worms. When the central nervous system is involved, it is often due to an inflammatory reaction to deposited eggs, leading to a CSF picture marked by lymphocytosis and eosinophilia. Schistosome eggs incite a granulomatous inflammatory reaction in tissues, including the brain or spinal cord. This immune response can lead to neurological symptoms and characteristic CSF findings. The inflammation may persist until the parasitic infection is cleared and the immune response is subdued. Patients with neuroschistosomiasis may present with headaches, seizures, focal neurological deficits, or other signs of meningeal irritation. The presence of eosinophils in the CSF is a strong indicator of parasitic infection, and in endemic areas, schistosomiasis should be considered. The differential diagnosis of eosinophilic meningitis includes parasitic infections such as Angiostrongylus cantonensis and Gnathostoma spinigerum, as well as certain fungal infections. Epidemiological history, serologic tests, and imaging studies aid in reaching the diagnosis of neuroschistosomiasis. Praziquantel is the first-line treatment for all forms of schistosomiasis, including neuroschistosomiasis. The typical dosing is 40\u201360 mg/kg in divided doses on the same day, often repeated after a few weeks. Adjunctive corticosteroids are commonly used to mitigate the inflammatory response in neuroschistosomiasis. Praziquantel is generally considered safe during pregnancy and lactation, with current guidelines indicating that the benefits outweigh any potential risks when treatment of schistosomiasis is indicated. Option A (Praziquantel) is the established drug of choice for schistosomiasis. Other options that might be antifungals or antimicrobials are not effective against trematode infections, making praziquantel the correct answer. \u2022 Eosinophilic meningitis in an endemic area should prompt consideration of parasitic causes like schistosomiasis. \u2022 Praziquantel is the mainstay of treatment for all schistosome infections. \u2022 Adjunctive steroids can be helpful in managing the inflammatory response in neuroschistosomiasis. Recent WHO guidelines and clinical studies continue to support praziquantel as the treatment of choice for schistosomiasis, including its neurosystem manifestations, with increasing emphasis on its safety in pregnancy and lactation.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario about mucormycosis (nasal dark lesion and history of DM)",
    "option_a": "mucormycosis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Mucormycosis is an aggressive, invasive fungal infection caused by fungi in the order Mucorales. It most commonly affects individuals with uncontrolled diabetes mellitus (especially those in diabetic ketoacidosis) and other immunocompromised states. The classic presentation involves rhinocerebral involvement with necrotic (black) lesions in the nasal cavity or palate. The fungi (such as Rhizopus species) invade blood vessels, leading to thrombosis, ischemia, and tissue necrosis. In diabetic patients, high blood sugar levels and acidosis impair neutrophil chemotaxis and phagocytosis, creating an environment in which the fungus can thrive. Patients typically present with facial pain, nasal congestion, and black necrotic eschar in the nasal mucosa or palate. The infection can rapidly spread to involve the orbit and brain if not promptly diagnosed and treated. The diagnosis is supported by imaging studies (CT or MRI) to assess the extent of invasion and confirmed by tissue biopsy with histopathological examination showing broad, aseptate hyphae with right-angle branching. Differential diagnoses include other invasive fungal infections such as aspergillosis, which typically has septate hyphae with acute angle branching. The current guidelines recommend an aggressive combined approach: first-line therapy is surgical debridement of necrotic tissues combined with high-dose intravenous amphotericin B. Control of the underlying metabolic condition (e.g., tight glycemic control in diabetics) is essential. Second-line therapies may include posaconazole or isavuconazole for patients who are intolerant to amphotericin B. In pregnancy and lactation, amphotericin B remains the treatment of choice since it has a relatively safe profile (Category B) compared to the potential risk of untreated invasive fungal infection. Option A (mucormycosis) is the correct answer given the patient\u2019s background of diabetes and the typical nasal dark lesion seen in rhinocerebral mucormycosis. The absence of other options in the MCQ further confirms that A is the intended correct response. 1. A black necrotic lesion in a diabetic patient is highly suggestive of mucormycosis. 2. Early diagnosis and prompt surgical debridement combined with antifungal therapy are critical to improve survival. Recent studies and guideline updates emphasize early multimodal management. There is ongoing research into new antifungal agents and adjunctive therapies, but amphotericin B remains the cornerstone of treatment.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "HIV patient on HAART (not complaint) developed PML what to do?",
    "option_a": "HAART",
    "option_b": "Steroids",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the reactivation of the JC virus, predominantly in immunocompromised patients such as those with HIV/AIDS. In PML, the JC virus infects oligodendrocytes, leading to lytic destruction and demyelination. This process results in multifocal, non-inflammatory lesions primarily in the white matter. Immune reconstitution is key to controlling the infection. PML typically presents with subacute focal neurological deficits including motor weakness, visual disturbances, and cognitive dysfunction. In an HIV patient already on HAART, immune reconstitution via continued therapy is crucial. Diagnosis is typically made with brain MRI showing multifocal white matter lesions without mass effect, and confirmed with JC virus PCR in the cerebrospinal fluid. Differential diagnoses include HIV-associated neurocognitive disorders and CNS lymphoma. The cornerstone of management in PML is optimizing immune function. The first-line management involves continuing (or initiating) highly active antiretroviral therapy (HAART). There is no proven antiviral therapy directly targeting the JC virus. In cases with immune reconstitution inflammatory syndrome (IRIS), corticosteroids might be considered, but they are not routine therapy for asymptomatic or uncomplicated cases. In pregnant or lactating women with HIV, HAART is also the recommended treatment owing to its dual benefit for the mother and prevention of mother-to-child transmission. Option A, which suggests continuing HAART, is correct. Steroids (Option B) are not indicated unless there is evidence of IRIS with severe inflammatory complications, which is not the case in a patient who is not clearly symptomatic or showing signs of inflammatory deterioration. 1. PML lesions are typically non-enhancing on MRI, helping to differentiate them from other CNS lesions. 2. The primary treatment remains immune restoration via HAART rather than direct antiviral or immunosuppressive therapies. Recent studies continue to support the strategy of immune reconstitution as the main therapy for PML. There is ongoing research into adjunctive treatments, but HAART remains the gold standard per current clinical guidelines.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with meningitis came from Alhaji found to have meningococcal meningitis what to give prophylaxis to the close contact",
    "option_a": "Ciprofloxacin (adult) or ceftriaxone (age <15y)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Meningococcal meningitis is a life-threatening bacterial infection caused by Neisseria meningitidis. Given its highly contagious nature, prophylaxis for close contacts is essential to prevent secondary cases. Neisseria meningitidis colonizes the nasopharynx and can invade the bloodstream, triggering a fulminant inflammatory response and meningitis. The high carriage rate emphasizes the need for prophylactic measures in close contacts to eradicate nasopharyngeal carriage. Close contacts of an infected individual are at high risk of developing meningococcal disease. This necessitates timely administration of prophylactic antibiotics to halt bacterial transmission. Definitive diagnosis is made via lumbar puncture with CSF analysis, Gram stain, and culture. Differential diagnoses include other bacterial causes of meningitis such as Streptococcus pneumoniae and Haemophilus influenzae, which have different prophylactic strategies for contacts. First-line prophylaxis for adult close contacts is a single dose of ciprofloxacin, whereas for children under the age of 15 (or in special populations such as pregnant women where fluoroquinolones are contraindicated), ceftriaxone is recommended. Alternative prophylactic agents include rifampin. In pregnant and lactating women, ceftriaxone is preferred over ciprofloxacin due to safety profiles. Option A is correct because it correctly identifies ciprofloxacin as the prophylactic agent for adults and ceftriaxone for those younger than 15 years of age, aligning with current public health guidelines for meningococcal meningitis prophylaxis. 1. Early prophylaxis in close contacts is crucial to prevent secondary spread of meningococcal disease. 2. Adjust prophylactic regimens based on age and pregnancy status to ensure safety. Guidelines from the CDC and WHO continue to endorse these prophylactic measures, and recent reviews emphasize the importance of tailoring prophylaxis (e.g., avoiding fluoroquinolones in children and pregnant women) in high-risk populations.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following infection that can cause internuclear ophthalmoplegia (INO)? (all of them can cause?!)",
    "option_a": "TB",
    "option_b": "HIV",
    "option_c": "cysticercosis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A, B, C",
    "subspecialty": "Neuro-infectious",
    "explanation": "Internuclear ophthalmoplegia (INO) is a disorder of ocular motility resulting from a lesion in the medial longitudinal fasciculus (MLF), a key neural tract involved in the coordination of eye movements. Although most commonly associated with demyelinating diseases like multiple sclerosis or vascular insults, INO can also occur secondary to focal infections. INO arises when an infectious process (or other lesion) affects the MLF in the brainstem, disrupting the neural signals that coordinate conjugate gaze. Infections can lead to localized inflammation, demyelination, or space-occupying lesions that impinge on the MLF. Clinically, INO is characterized by impaired adduction of the affected eye with abducting nystagmus in the contralateral eye. In infectious cases, symptoms may be accompanied by other signs of focal brainstem involvement. Several infections can lead to INO by forming lesions near the MLF. Magnetic resonance imaging (MRI) is the diagnostic modality of choice to localize brainstem lesions. Differential diagnoses include demyelinating diseases (e.g., multiple sclerosis), brainstem infarcts, and tumors. Detailed clinical history and additional laboratory tests (e.g., CSF analysis, serologies) help to differentiate infectious etiologies such as TB, HIV-associated pathology, or neurocysticercosis. Treatment of INO is directed at the underlying infection. For tubercular involvement, standard antitubercular therapy is indicated. HIV-related INO is managed by optimizing antiretroviral therapy, and neurocysticercosis is treated with antiparasitic agents (such as albendazole) along with corticosteroids to decrease inflammation if indicated. In pregnancy and lactation, the choice of therapy must balance maternal benefits and fetal/neonatal safety. For example, antitubercular drugs like isoniazid and rifampin are generally safe in pregnancy under close monitoring. Option A (TB): There are case reports documenting tubercular involvement of the brainstem resulting in INO. Option B (HIV): HIV can cause direct neurological complications or predispose to opportunistic infections (e.g., PML) that lead to INO. Option C (cysticercosis): Neurocysticercosis can form cysts in the brainstem causing focal lesions impactful enough to result in INO. The marked answer (B alone) is incorrect because all three infections provided (TB, HIV, and cysticercosis) have been reported as potential causes of INO. 1. INO is recognized by impaired adduction in one eye with accompanying nystagmus in the abducting eye. 2. A thorough workup to identify an infectious etiology is essential when INO is diagnosed, especially in endemic areas for TB and cysticercosis or in immunocompromised patients. Recent case reports and small case series have expanded the list of infectious causes of INO, underscoring that aside from the classic demyelinating and vascular etiologies, infections such as tuberculosis, HIV-associated pathology, and neurocysticercosis can affect the brainstem. Current guidelines emphasize a comprehensive diagnostic approach to tailor management appropriately.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Meningitis case, asked about prophylactic to give for family members?",
    "option_a": "Ciprofloxacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Meningococcal meningitis is a bacterial infection caused by Neisseria meningitidis. When a case is identified, it is essential to provide prophylactic antibiotics to close contacts such as family members to eliminate nasopharyngeal carriage and prevent secondary cases. Neisseria meningitidis colonizes the nasopharynx and may breach the blood\u2013brain barrier to cause meningitis. Prophylaxis works by rapidly eradicating the organism from the nasopharynx, interrupting its transmission. Several agents, including rifampin, ciprofloxacin, and ceftriaxone, act by inhibiting bacterial replication or cell wall synthesis, with choices tailored by patient factors such as age and pregnancy status. Family members or close contacts are at risk because the bacteria spreads via respiratory droplets. In outbreaks or single cases, early prophylactic treatment minimizes morbidity and mortality associated with invasive disease. Definitive diagnosis of meningococcal meningitis involves lumbar puncture with CSF analysis (cell counts, protein, glucose), Gram stain, culture, and possibly nucleic acid amplification tests. Prophylaxis is indicated once the diagnosis of meningococcal disease is established. First-line prophylaxis for adult, non-pregnant close contacts is a single dose of ciprofloxacin (typically 500 mg orally). For pregnant contacts or where ciprofloxacin is contraindicated, rifampin (600 mg orally every 12 hours for 2 days) or single-dose ceftriaxone (intramuscular) are recommended. The guidelines stress rapid initiation to curb transmission. Option A (Ciprofloxacin) is correct for adult prophylaxis in meningococcal meningitis. Although other agents like rifampin are also acceptable, ciprofloxacin is widely used especially because of its single-dose regimen. The absence of other options does not detract from the correctness of ciprofloxacin in adult, non-pregnant contacts. 1. Always assess pregnancy status when selecting prophylactic agents; ciprofloxacin is contraindicated in pregnancy. 2. Prophylaxis is effective only when given promptly to close contacts of a confirmed case. 3. Be aware of alternative regimens such as rifampin and ceftriaxone based on patient-specific factors. Recent CDC guidelines continue to recommend ciprofloxacin as a first-line prophylactic agent for adult contacts in cases of meningococcal disease. Studies show a low resistance profile with a single 500 mg dose, reinforcing its utility in outbreak control.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]